Kamont Tablet contains Levocetirizine 5mg and Montelukast 10mg, combining an antihistamine and a leukotriene receptor antagonist to provide effective relief from allergic conditions. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, rhinorrhea, nasal congestion, and itching associated with allergic rhinitis and chronic urticaria. Montelukast acts by blocking leukotriene D4 receptors in the airway, preventing bronchoconstriction and inflammation, which makes it beneficial in managing asthma and allergic rhinitis. Kamont Tablet is indicated for the treatment of seasonal and perennial allergic rhinitis, chronic idiopathic urticaria, and as an adjunct therapy in asthma to improve symptom control and reduce exacerbations. The combination offers a synergistic effect by targeting multiple pathways involved in allergic responses, enhancing patient compliance by reducing pill burden. It is generally well-tolerated; however, potential side effects may include headache, fatigue, dry mouth, and gastrointestinal disturbances. Kamont Tablet should be used under medical supervision, with dosage adjustments in special populations such as children and patients with hepatic or renal impairment. It is contraindicated in patients with known hypersensitivity to its components. Regular monitoring and adherence to prescribed regimens are advised to achieve optimal therapeutic outcomes.